Single Cell Transcriptomics Could Help Eradicate Leukemia More Effectively
Cancer-causing leukemic stem cells are present in small numbers in patients and are hard to identify using conventional techniques. A single-cell omics approach can identify mutational status and gene expression in stem cells from acute myeloid leukemia patients and locate disease-causing cells for later targeting.
Oncology Analytics’ Series B Yields $21M
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
Triple negative breast cancer might not actually be ‘breast cancer’
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
Melanoma Vaccine from NeoVox Shows Anti-Tumor Response Four Years Later
In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients remained alive and six patients had no signs of active disease.
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Agilent Revs up Precision Medicine Push with Planned Resolution Bioscience Acquisition
Agilent Technologies announced yesterday it has agreed to buy Resolution Bioscience for up to $695 million, in a deal aimed at broadening it position in the precision medicine space by offering an array of next-generation sequencing-based diagnostics.
Six Precision Medicine Companies Making Their Mark in 2020
This year’s list of innovative companies have all found, or developed, technology solutions that have allowed them to become innovators in their niche.
myDNA Merges with Gene by Gene, Uniting Personalized Genetics Pioneers
myDNA and Gene by Gene said the combined companies would be a leading global provider of genealogy, pharmacogenomics, and nutrigenomic services.
“Refined” COVID-19 Vaccine Program of Sanofi and GSK Launches Phase II Trial
Sanofi and GlaxoSmithKline (GSK) said today they have begun a new mid-stage study of a “refined” formulation of their adjuvanted recombinant protein-based candidate, with plans to advance to Phase III next quarter and reach the market by year’s end.
Cell and Gene Therapy Clinical Trials
Sponsor: ICONThe promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.